What is Zacks Research's Forecast for Medifast Q2 Earnings?

Medifast, Inc. (NYSE:MED - Free Report) - Zacks Research dropped their Q2 2025 earnings per share estimates for Medifast in a note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the specialty retailer will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.24. The consensus estimate for Medifast's current full-year earnings is $0.51 per share. Zacks Research also issued estimates for Medifast's Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.10 EPS, FY2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.14 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.75 EPS, Q1 2027 earnings at $0.13 EPS and FY2027 earnings at $0.51 EPS.

Medifast (NYSE:MED - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). The company had revenue of $115.73 million for the quarter, compared to analyst estimates of $114.85 million. Medifast had a return on equity of 10.64% and a net margin of 0.35%.

A number of other research analysts have also commented on the company. Wall Street Zen raised Medifast from a "hold" rating to a "buy" rating in a report on Thursday, May 1st. DA Davidson decreased their price objective on Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a report on Wednesday, February 19th.

Medifast Stock Performance

MED traded up $0.31 during trading hours on Thursday, reaching $13.72. The company's stock had a trading volume of 80,700 shares, compared to its average volume of 293,993. Medifast has a 52 week low of $11.57 and a 52 week high of $26.53. The company's 50-day moving average is $13.08 and its 200-day moving average is $15.39. The firm has a market cap of $150.74 million, a PE ratio of 76.19 and a beta of 0.96.

Institutional Investors Weigh In On Medifast

A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. grew its stake in Medifast by 156.1% in the third quarter. JPMorgan Chase & Co. now owns 57,455 shares of the specialty retailer's stock valued at $1,100,000 after acquiring an additional 35,017 shares during the period. Wells Fargo & Company MN raised its stake in shares of Medifast by 23.5% in the fourth quarter. Wells Fargo & Company MN now owns 6,459 shares of the specialty retailer's stock valued at $114,000 after buying an additional 1,227 shares during the period. Barclays PLC raised its stake in shares of Medifast by 15.1% during the 4th quarter. Barclays PLC now owns 16,194 shares of the specialty retailer's stock valued at $285,000 after purchasing an additional 2,127 shares during the period. Amundi bought a new stake in shares of Medifast during the 4th quarter valued at $374,000. Finally, American Century Companies Inc. increased its stake in Medifast by 3.4% in the 4th quarter. American Century Companies Inc. now owns 244,185 shares of the specialty retailer's stock worth $4,303,000 after acquiring an additional 8,058 shares during the last quarter. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.